ClinicalTrials.Veeva

Menu

Natural Killer (NK) Cells Following Bariatric Surgery

H

Hadassah Medical Center

Status

Unknown

Conditions

Natural Killer Cell Deficiency, Familial Isolated

Treatments

Procedure: sleeve gastrectomy , roux-en-y gastric bypass

Study type

Observational

Funder types

Other

Identifiers

NCT02732535
0298-15-HMO-CTIL

Details and patient eligibility

About

This study will determine the role of the NK cells before and after bariatric surgery. The investigators selected patients with NAFLD.

A Fibroscan evaluation will be assessed as a new modality to evaluate liver fibrosis.

Full description

All morbidly obese patients who are candidates for a bariatric procedure in the investigators institution who has a fatty liver in their routine preoperative US will undergo a fibroscan to assess the degree of liver fibrosis preoperatively in addition to a blood sample that will be withdrawn from those participants to isolate the NK cells and to assess their activities by the assessment of the active form of NK cells (CD107a) using the spectrometry (FACS) analysis.

The investigators will also collect other clinical data including comorbidities (hypertension, diabetes mellitus and hyperlipidemia) in addition to the following routine blood test( complete blood count, creatinine, urea, International normalized ratio, liver function test, HBa1C, cholesterol, HDL, LDL, triglycerides, vitamin D, vitamin B12, potassium, sodium, albumin, bilirubin, C- reactive protein, iron, ferritin and transferrin).

All of the above mentioned tests including the NK cells and the fibroscan will be examined for all participants in 3, 6, 12 months postoperatively.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • age from 18-65
  • body mass index above 30 with comorbidity or above 35 with or without comorbidity
  • evidence of hepatic fibrosis in routine preoperative US

Exclusion criteria

  • patient with known other liver disease such as autoimmune or alcoholic hepatitis
  • patient that take hepatotoxic medication or hormonal treatment
  • active alcohol abuse above 20 gram per day
  • Drug abuse
  • patient refusal
  • pregnancy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems